Reduction in length of immunotherapy treatment for hard-to-treat melanoma shows promise in clinical trial

Reducing the length of immunotherapy treatment for an advanced skin cancer did not significantly diminish disease control when compared to giving treatments over a longer period, according to research led by the Universities of Sheffield and Leeds and Sheffield Teaching Hospitals NHS Foundation Trust.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup